{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:48:07Z","timestamp":1766587687574,"version":"3.44.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13760-025-02782-3","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T21:19:02Z","timestamp":1744319942000},"page":"989-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Migraine treatment with CGRP monoclonal antibodies: patient evaluation of a mandatory treatment holiday in Belgium"],"prefix":"10.1007","volume":"125","author":[{"given":"Ruben","family":"De Praeter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien","family":"Tuerlinckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Schoenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabet","family":"Boon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona Liliana","family":"Sava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"Delmotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adinda","family":"De Pauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Van Dycke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Van Humbeeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Versijpt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2782_CR1","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia (2018);38(1):1-211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"2","key":"2782_CR2","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A et al (2022) Global, regional, and National burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163(2):e293\u2013e309. https:\/\/doi.org\/10.1097\/j.pain.0000000000002275","journal-title":"Pain"},{"issue":"1","key":"2782_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-022-01510-z","volume":"23","author":"AK Eigenbrodt","year":"2022","unstructured":"Eigenbrodt AK, Christensen RH, Ashina H et al (2022) Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency. J Headache Pain 23(1):1\u201313. https:\/\/doi.org\/10.1186\/s10194-022-01510-z","journal-title":"J Headache Pain"},{"issue":"2","key":"2782_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28(2):183\u2013187. https:\/\/doi.org\/10.1002\/ana.410280213","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"2782_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/brain\/117.3.427","volume":"117","author":"PJ Goadsby","year":"1994","unstructured":"Goadsby PJ, Edvinsson L (1994) Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain J Neurol 117(Pt 3):427\u2013434. https:\/\/doi.org\/10.1093\/brain\/117.3.427","journal-title":"Brain J Neurol"},{"issue":"1","key":"2782_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP May play a causative role in migraine. Cephalalgia Int J Headache 22(1):54\u201361. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00310.x","journal-title":"Cephalalgia Int J Headache"},{"issue":"10","key":"2782_CR7","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0333102410368444","volume":"30","author":"JM Hansen","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia Int J Headache 30(10):1179\u20131186. https:\/\/doi.org\/10.1177\/0333102410368444","journal-title":"Cephalalgia Int J Headache"},{"issue":"5","key":"2782_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","volume":"59","author":"S Iyengar","year":"2019","unstructured":"Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache 59(5):659\u2013681. https:\/\/doi.org\/10.1111\/head.13529","journal-title":"Headache"},{"issue":"2","key":"2782_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","volume":"17","author":"A Charles","year":"2018","unstructured":"Charles A (2018) The pathophysiology of migraine: implications for clinical management. Lancet Neurol 17(2):174\u2013182. https:\/\/doi.org\/10.1016\/S1474-4422(17)30435-0","journal-title":"Lancet Neurol"},{"key":"2782_CR10","doi-asserted-by":"publisher","first-page":"111557","DOI":"10.1016\/j.biopha.2021.111557","volume":"139","author":"J Khan","year":"2021","unstructured":"Khan J, Asoom LIA, Sunni AA et al (2021) Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother Biomedecine Pharmacother 139:111557. https:\/\/doi.org\/10.1016\/j.biopha.2021.111557","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"issue":"1","key":"2782_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s10194-023-01644-8","volume":"24","author":"A Labastida-Ram\u00edrez","year":"2023","unstructured":"Labastida-Ram\u00edrez A, Caronna E, Gollion C et al (2023) Mode and site of action of therapies targeting CGRP signaling. J Headache Pain 24(1):125. https:\/\/doi.org\/10.1186\/s10194-023-01644-8","journal-title":"J Headache Pain"},{"issue":"3","key":"2782_CR12","doi-asserted-by":"publisher","first-page":"033310242311521","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia 43(3):03331024231152169. https:\/\/doi.org\/10.1177\/03331024231152169","journal-title":"Cephalalgia"},{"issue":"1","key":"2782_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI et al (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 24(1):1\u201314. https:\/\/doi.org\/10.1186\/s10194-023-01594-1","journal-title":"J Headache Pain"},{"issue":"1","key":"2782_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M et al (2022) European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u2013\u20092022 update. J Headache Pain 23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"2782_CR15","unstructured":"Belgisch Centrum voor Farmacotherapeutische Informatie. Gecommentarieerd geneesmiddelenrepertorium. Accessed January 30 (2024) https:\/\/www.bcfi.be\/nl\/chapters"},{"issue":"1","key":"2782_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-023-01539-8","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Lyons HS, Boucherie DM et al (2023) The sense of stopping migraine prophylaxis. J Headache Pain 24(1):9. https:\/\/doi.org\/10.1186\/s10194-023-01539-8","journal-title":"J Headache Pain"},{"key":"2782_CR17","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.ynpai.2022.100094","volume":"12","author":"W Rattanawong","year":"2022","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2022) Neurobiology of migraine progression. Neurobiol Pain 12:100094. https:\/\/doi.org\/10.1016\/j.ynpai.2022.100094","journal-title":"Neurobiol Pain"},{"issue":"1","key":"2782_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y","journal-title":"J Headache Pain"},{"issue":"5","key":"2782_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW et al (2018) Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia Int J Headache 38(5):815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia Int J Headache"},{"issue":"10","key":"2782_CR20","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW et al (2020) Guidelines of the international headache society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia Int J Headache 40(10):1026\u20131044. https:\/\/doi.org\/10.1177\/0333102420941839","journal-title":"Cephalalgia Int J Headache"},{"key":"2782_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/JMDH.S104807","volume":"9","author":"A Althubaiti","year":"2016","unstructured":"Althubaiti A (2016) Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc 9:211\u2013217. https:\/\/doi.org\/10.2147\/JMDH.S104807","journal-title":"J Multidiscip Healthc"},{"key":"2782_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.12688\/f1000research.17611.2","volume":"8","author":"K Wartolowska","year":"2019","unstructured":"Wartolowska K (2019) The Nocebo effect as a source of bias in the assessment of treatment effects. F1000Research 8:5. https:\/\/doi.org\/10.12688\/f1000research.17611.2","journal-title":"F1000Research"},{"issue":"9","key":"2782_CR23","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/pme.12505","volume":"15","author":"P Kindelan-Calvo","year":"2014","unstructured":"Kindelan-Calvo P, Gil-Mart\u00ednez A, Paris-Alemany A et al (2014) Effectiveness of therapeutic patient education for adults with migraine. A systematic review and Meta-Analysis of randomized controlled trials. Pain Med 15(9):1619\u20131636. https:\/\/doi.org\/10.1111\/pme.12505","journal-title":"Pain Med"},{"issue":"5","key":"2782_CR24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/ene.15260","volume":"29","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol 29(5):1505\u20131513. https:\/\/doi.org\/10.1111\/ene.15260","journal-title":"Eur J Neurol"},{"issue":"4\u20135","key":"2782_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/03331024211046617","volume":"42","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli B, Terhart M, Overeem LH et al (2022) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia Int J Headache 42(4\u20135):326\u2013334. https:\/\/doi.org\/10.1177\/03331024211046617","journal-title":"Cephalalgia Int J Headache"},{"issue":"1","key":"2782_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain 22(1):154. https:\/\/doi.org\/10.1186\/s10194-021-01363-y","journal-title":"J Headache Pain"},{"issue":"7","key":"2782_CR27","doi-asserted-by":"publisher","first-page":"e2662","DOI":"10.1002\/brb3.2662","volume":"12","author":"M Nsaka","year":"2022","unstructured":"Nsaka M, Scheffler A, Wurthmann S et al (2022) Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Brain Behav 12(7):e2662. https:\/\/doi.org\/10.1002\/brb3.2662","journal-title":"Brain Behav"},{"issue":"11\u201312","key":"2782_CR28","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein AR, Agosti R, Gobbi C et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment\u2013 a real-life cohort study. Cephalalgia 41(11\u201312):1181\u20131186. https:\/\/doi.org\/10.1177\/03331024211014616","journal-title":"Cephalalgia"},{"issue":"1","key":"2782_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s10194-021-01368-7","volume":"22","author":"M Terhart","year":"2021","unstructured":"Terhart M, Mecklenburg J, Neeb L et al (2021) Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain 22(1):158. https:\/\/doi.org\/10.1186\/s10194-021-01368-7","journal-title":"J Headache Pain"},{"key":"2782_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-024-01259-x","author":"S Cho","year":"2024","unstructured":"Cho S, Kim BK (2024) Long-Term outcome after discontinuation of CGRP-Targeting therapy for migraine. Curr Pain Headache Rep Published Online April 29. https:\/\/doi.org\/10.1007\/s11916-024-01259-x","journal-title":"Curr Pain Headache Rep Published online April"},{"issue":"6","key":"2782_CR31","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1212\/CPJ.0000000000001112","volume":"11","author":"F Schiano di Cola","year":"2021","unstructured":"Schiano di Cola F, Caratozzolo S, Venturelli E et al (2021) Erenumab discontinuation after 12-Month treatment: A multicentric, observational Real-Life study. Neurol Clin Pract 11(6):e834\u2013e839. https:\/\/doi.org\/10.1212\/CPJ.0000000000001112","journal-title":"Neurol Clin Pract"},{"issue":"5","key":"2782_CR32","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725. https:\/\/doi.org\/10.1111\/ene.14715","journal-title":"Eur J Neurol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02782-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-025-02782-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02782-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:22:56Z","timestamp":1756304576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-025-02782-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1007\/s13760-025-02782-3","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"type":"print","value":"0300-9009"},{"type":"electronic","value":"2240-2993"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}